{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-000355","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.714366+00:00","generated_at":"2026-05-16T03:53:55.114900+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entera Bio appoints former Pfizer exec Geno J. Germano as Chairman, replacing Gerald Lieberman","bullets":["Geno Germano appointed Class III director and Chairman of the Board effective February 4, 2026.","Gerald Lieberman resigned as Chairman and Director effective Feb 4, 2026, no disagreement.","Germano led Pfizer's $14B Global Innovative Pharma business as Group President until 2016.","Entera plans Phase 3 registrational study for EB613 (osteoporosis) and first-in-human for Long-Acting Oral PTH (hypoparathyroidism) in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-000355","json":"https://secwatch.observer/filing/0001178913-26-000355.json","markdown":"https://secwatch.observer/filing/0001178913-26-000355.md","text":"https://secwatch.observer/filing/0001178913-26-000355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/0001178913-26-000355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/zk2634303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:53:55.114900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}